alexa Biological Therapies And Lupus Nephritis | 17553
ISSN: 2161-0959

Journal of Nephrology & Therapeutics
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

3rd International Conference on Nephrology & Therapeutics

Luis Enrique Herrera Jim?nez
Accepted Abstracts: J Nephrol Ther
DOI: 10.4172/2161-0959.S1.016
Abstract
S ystemic lupus erythematosus (SLE), is a clinical syndrome characterized for multi organic involvement with no currently known cure, nearly 80% of patients have persistently active disease or frequent flares. Renal involvement represents one of the most common causes of morbidity, almost 40-50% of patients during the course of the disease experience some degree of renal damage and the risk of end-stage renal disease is 10-30%. Although the drugs now approved for the treatment of the disease have shown a positive impact in the prognosis of the disease, there are still some patients who do not respond to standard treatment with cyclophosphamide or mycophenolate mofetil (MPA). B cells play a central role in the pathogenesis of the disease, they are precursors for plasma cells that secrete pathogenic auto antibodies, on the other hand T cells also participate by activating B cells. Therefore some of the current therapies under active investigation are directed against molecular targets known to be implicated in the pathogenesis of the disease involving B and T cells. Rituximab -an anti CD 20 antibody- has been used since several years in SLE with some success, nevertheless it is not approved by the FDA for the treatment of the disease. In the context of lupus nephritis, Rituximab was tested in the LUNAR trial, which fail to demonstrate renal response compared with the standard treatment (MPA and prednisone). In March 2011, the FDA approved the first biological therapy for the treatment of LES, Belimumab a humanized monoclonal anti body directed against a stimulator of B cells (BLyS) that showed clinical and serological response in two randomized, multi center, phase 3 clinical trails (the BLISS 76 and BLISS 52), however both trial excluded patients with severe renal manifestations. A post-hoc analysis of renal outcomes of the BLISS trials showed some renal response at the end of the follow up. There are currently several trials involving biologic drugs directed against different targets implicated in the pathogenesis of SLE and other autoimmune diseases. Reviewing some of the most promising biologic drugs in the treatment of lupus nephritis represents an attractive topic
Biography
Luis Enrique Herrera Jim?nez is MD, Nephrology and Internal Medicine, Hemodialysis unit Durango ́s General Hospital and Professor of physiology at medical school. He is a speaker at national Nephropatology and Nephrology meetings, Instructor of Basic life support and advanced Cardiovascular support (BLS and ACLS) certified by the American Heart association.
image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

+1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

engineeringjourn[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
Leave Your Message 24x7